Tag: with

2023 Genitourinary oncology (GU) Cancer

ESMO 2023 GU Cancer Highlights – SunRISE-1, EV-302, PSMAfore

Post author By atif
Post date November 6, 2023

In discussion with Dr. Rana McKay, covering the ESMO 2023 GU Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. McKay:

– SunRISE-1 – TAR-200 in Combination with Cetrelimab Versus TAR-200 Versus Cetrelimab in NMIBC unpresponsive to BCG – with TAR-200 mono therapy achieving 77% overall complete response rate

– EV-302 – Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Metastatic Urothelial Cancer, which showed impressive PFS and OS

– PSMAfore – 177Lu-PSMA-617 Versus Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer with impressive responsiveness

Tags 2023, brothers, Cancer, ESMO, ESMO Lung Cancer, Highlights, onc, oncology, Rahul Gosain, rohit gosain, with

Algorithms Journal of Hematology

How to Treat MGUS and Smoldering Myeloma with Dr. S. Vincent Rajkumar

Post author By control_admin
Post date July 27, 2023

Discussing how to treat MGUS (Monoclonal gammopathy of undetermined significance) and Smoldering Myeloma using an algorithm with Dr. S. Vincent Rajkumar. We covered MGUS and smoldering myeloma in great detail, following with how these patients should be monitored and if any of these patients should be treated. Dr. S. Vincent Rajkumar is a world-renowned physician who specializes in plasma cell disorders – Professor of Medicine at the Mayo Clinic Comprehensive Cancer Center.

Tags 2023, and, Approval, brothers, Cancer, Dr. S. Vincent Rajkumar, how, MGUS, Myeloma, onc, oncology, Smoldering, to, treat, with

Algorithms Journal of Hematology

How to Treat Multiple Myeloma with Dr. Jens Hillengass

Post author By control_admin
Post date July 20, 2023

Discussing how to treat multiple myeloma using an algorithm with Dr. Jens Hillengass. We cover the first line, following that recurrence and refractory myeloma management in great detail. Dr. Jens Hillengass is the Chief of Myeloma, Professor of Oncology and Internal Medicine at the Roswell Park Comprehensive Cancer Center – University at Buffalo.

Tags 2023, brothers, Cancer, Dr. Jens Hillengass, how, Multiple, Myeloma, onc, oncology, to, treat, with

2023 ASCO

GI Cancer ASCO 2023 Highlights with Dr. Muhammad Shaalan Beg

Post author By control_admin
Post date June 29, 2023

Discussing GI (Gastrointestinal) Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Muhammad Shaalan Beg, Co-Leader Gastrointestinal Oncology, Adjunct Associate Professor of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center. Covering three important studies:

– PROSPECT: ph III trial of neoad chemoRT vs neoadj FOLFOX chemo with selective use of chemoRT, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC)

– NORPACT-1: Short-course neoadj FOLFIRINOX vs upfront surgery for resectable pancreatic head cancer

– NAPOLI 3: ph III trial in mets pancreatic ductal adenocarcinoma pts, liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) vs nab-paclitaxel + gemcitabine

– IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) from the phase III IMbrave050 trial of adj atezo + bev vs active surveillance in pts with HCC

Tags 2023, ASCO, brothers, Cancer, Dr. Muhammad Shaalan Beg, GI, Highlights, onc, oncology, Rahul Gosain, rohit gosain, with

2023 ASCO

Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

Post author By control_admin
Post date June 22, 2023

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies:

– ADAURA trial update with increase OS with adjuvant Osimertinib

– KEYNOTE 789 – Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant

– KEYNOTE 671 – Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

Tags 2023, ASCO, ASCO 2023, brothers, Cancer, Dr. Charu Aggarwal, Highlights, Lung, onc, oncology, Rahul Gosain, rohit gosain, with

2023 ASCO

Breast Cancer ASCO 2023 Highlights with Dr. Stephanie Graff

Post author By control_admin
Post date June 15, 2023

Discussing Breast Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies:

– NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients

– SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients

– X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer

Tags 2023, ASCO, ASCO 2023, Breast, brothers, Cancer, Dr. Stephanie Graff, Highlights, onc, oncology, Rahul Gosain, rohit gosain, with

Algorithms Gastrointestinal Cancer Journal

Colon Cancer Algorithm Discussion with Dr. Cathy Eng

Post author By control_admin
Post date May 8, 2023

Discussing the management of Colon Cancer using the algorithm with Dr. Cathy Eng, MD, Professor of Medicine at the Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical & Medical Oncology, Co-Leader Gastrointestinal Cancer Research Program, Co-Director of GI Oncology Program.

Tags 2023, Algorithm, brothers, Cancer, Colon, discussion, Dr. Cathy Eng, onc, oncology, Rahul Gosain, rohit gosain, with

Algorithms Journal of Breast Cancer

HR+ Breast Cancer Management with Dr. Margaret Gatti-Mays

Post author By control_admin
Post date April 20, 2023

Discussing the management of Hormone Receptor Positive Breast Cancer with Dr. Margaret Gatti-Mays, Section Chief of the Breast Medical Oncology at the Ohio State University Comprehensive Cancer Center, The James Cancer Hospital & Solove Research Institute. In our discussion with Dr. Gatti-Mays we cover the treatment algorithm of the hormone receptor-positive disease following the FDA expanding the adjuvant abemaciclib approval where one doesn’t need Ki-67 levels anymore, and new agents recently approved by the FDA – elacestrant, TDXD and sacituzumab providing more treatment options for our patients.

Tags Breast, brothers, Cancer, Dr. Margaret Gatti-Mays, HR+, Management, onc, oncology, Rahul Gosain, rohit gosain, with

Algorithms Journal of Breast Cancer

HR+ Invasive Lobular Carcinoma Management with Dr. Jason Mouabbi

Post author By control_admin
Post date April 10, 2023

Discussing the management of Invasive Lobular Carcinoma with Dr. Jason Mouabbi from the MD Anderson Cancer Center. We see different histologies in hormone receptor-positive breast cancer patients – we will focus on invasive lobular carcinoma in this video. Are these patients different than one with invasive ductal carcinoma? How does the prognosis differs?

Tags Breast, brothers, Cancer, Carcinoma, Dr. Jason Mouabbi, HR+, Invasive, Lobular, Management, onc, oncology, Rahul Gosain, rohit gosain, with

Algorithms Journal of Lung Cancer

Localized Non-Small Cell Lung Cancer (NSCLC) Algorithm Discussion with Dr. Charu Aggarwal

Post author By control_admin
Post date March 13, 2023

Discussing the management of Localized Non-Small Cell Lung Cancer (NSCLC) using the algorithm – with Dr. Charu Aggarwal, Associate Director – Penn Center for Precision Medicine, Associate Professor for Lung Cancer Excellence.

Tags (NSCLC), 2023, Algorithm, brothers, Cancer, Cell, discussion, Dr. Charu Aggarwal, Localized, Lung, Non-Small, onc, oncology, Rahul Gosain, rohit gosain, with

Quick Links

Contact

Subscribe Now

Dr. Rahul